JP2023546316A - 多価sting活性化組成物およびその使用法 - Google Patents
多価sting活性化組成物およびその使用法 Download PDFInfo
- Publication number
- JP2023546316A JP2023546316A JP2023515254A JP2023515254A JP2023546316A JP 2023546316 A JP2023546316 A JP 2023546316A JP 2023515254 A JP2023515254 A JP 2023515254A JP 2023515254 A JP2023515254 A JP 2023515254A JP 2023546316 A JP2023546316 A JP 2023546316A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sting
- composition according
- pc7a
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075560P | 2020-09-08 | 2020-09-08 | |
| US63/075,560 | 2020-09-08 | ||
| PCT/US2021/049365 WO2022055929A1 (en) | 2020-09-08 | 2021-09-08 | Polyvalent sting activating compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546316A true JP2023546316A (ja) | 2023-11-02 |
| JP2023546316A5 JP2023546316A5 (cg-RX-API-DMAC7.html) | 2024-09-11 |
Family
ID=80469374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515254A Pending JP2023546316A (ja) | 2020-09-08 | 2021-09-08 | 多価sting活性化組成物およびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12036319B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210707A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023546316A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230066019A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116490193A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021340623A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004271A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191593A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301190A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002797A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022055929A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114805309A (zh) * | 2022-06-07 | 2022-07-29 | 中国药科大学 | 苯并杂环类化合物及其制备方法、药物组合物和应用 |
| CN120000802A (zh) * | 2023-11-20 | 2025-05-16 | 北京大学 | 用于靶蛋白水解的聚合物及其制备方法和用途 |
| CN120242033B (zh) * | 2025-06-03 | 2025-08-22 | 合肥市第一人民医院 | 一种纳米组装体及其制备方法和应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019511483A (ja) * | 2016-03-02 | 2019-04-25 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 免疫療法のためのsting活性化ナノワクチン |
| WO2019092660A1 (en) * | 2017-11-10 | 2019-05-16 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| WO2019173587A1 (en) * | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019180683A1 (en) * | 2018-03-23 | 2019-09-26 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| US20200078312A1 (en) * | 2018-09-07 | 2020-03-12 | Wisconsin Alumni Research Foundation | Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment |
| JP2022536993A (ja) * | 2019-06-22 | 2022-08-22 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 生分解性超pH感受性ポリマー |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506408A (ja) | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 癌処置としてのstingアゴニストの使用 |
| EP3233089A4 (en) | 2014-12-17 | 2018-11-14 | Lipogen LLC | Method of treating cancer with cgamp or cgasmp |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| CA3078309A1 (en) * | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Methods for administering sting agonists |
| WO2019161171A1 (en) * | 2018-02-16 | 2019-08-22 | Sperovie Biosciences, Inc. | Nanoparticle formulations of sting agonists |
-
2021
- 2021-09-08 MX MX2023002797A patent/MX2023002797A/es unknown
- 2021-09-08 KR KR1020237010998A patent/KR20230066019A/ko active Pending
- 2021-09-08 CN CN202180071894.1A patent/CN116490193A/zh active Pending
- 2021-09-08 WO PCT/US2021/049365 patent/WO2022055929A1/en not_active Ceased
- 2021-09-08 CA CA3191593A patent/CA3191593A1/en active Pending
- 2021-09-08 BR BR112023004271A patent/BR112023004271A2/pt unknown
- 2021-09-08 EP EP21867478.6A patent/EP4210707A4/en active Pending
- 2021-09-08 IL IL301190A patent/IL301190A/en unknown
- 2021-09-08 AU AU2021340623A patent/AU2021340623A1/en active Pending
- 2021-09-08 JP JP2023515254A patent/JP2023546316A/ja active Pending
- 2021-09-08 US US17/469,111 patent/US12036319B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019511483A (ja) * | 2016-03-02 | 2019-04-25 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 免疫療法のためのsting活性化ナノワクチン |
| WO2019092660A1 (en) * | 2017-11-10 | 2019-05-16 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| WO2019173587A1 (en) * | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019180683A1 (en) * | 2018-03-23 | 2019-09-26 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| US20200078312A1 (en) * | 2018-09-07 | 2020-03-12 | Wisconsin Alumni Research Foundation | Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment |
| JP2022536993A (ja) * | 2019-06-22 | 2022-08-22 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 生分解性超pH感受性ポリマー |
Non-Patent Citations (5)
| Title |
|---|
| ADVANCED MATERIALS, vol. 30, JPN6026027945, 2018, pages 1803926 - 1, ISSN: 0005901447 * |
| J. IMMUNOL., vol. 199(11), JPN6025040924, 2017, pages 3840 - 3848, ISSN: 0005901444 * |
| JOURNAL OF BIOMATERIALS SCIENCE, POLYMER EDITION, vol. 31, no. 11, JPN6026027944, August 2020 (2020-08-01), pages 1385 - 1404, ISSN: 0005901446 * |
| MED. RES. REV., vol. 40, JPN6025040923, December 2019 (2019-12-01), pages 1117 - 1141, ISSN: 0005901445 * |
| NATURE NANOTECHNOLOGY, vol. 12, no. 7, JPN6026027946, 2017, pages 648 - 654, ISSN: 0005901448 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021340623A1 (en) | 2023-04-13 |
| CA3191593A1 (en) | 2022-03-17 |
| IL301190A (en) | 2023-05-01 |
| EP4210707A1 (en) | 2023-07-19 |
| MX2023002797A (es) | 2023-05-04 |
| KR20230066019A (ko) | 2023-05-12 |
| EP4210707A4 (en) | 2024-10-16 |
| US12036319B2 (en) | 2024-07-16 |
| WO2022055929A1 (en) | 2022-03-17 |
| BR112023004271A2 (pt) | 2023-04-04 |
| CN116490193A (zh) | 2023-07-25 |
| US20220071903A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12036319B2 (en) | Polyvalent sting activating compositions and uses thereof | |
| CN113660957A (zh) | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 | |
| JP2010526091A5 (cg-RX-API-DMAC7.html) | ||
| WO2017044803A1 (en) | Expression vector delivery system and use thereof for inducing an immune response | |
| JP7811545B2 (ja) | pH応答性ブロックコポリマー組成物、ミセル、及び使用の方法 | |
| US20240277854A1 (en) | Immolative cell-penetrating complexes for nucleic acid delivery to the lung | |
| JP2020517599A (ja) | 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート | |
| KR20230097142A (ko) | 치료용 pH 반응성 조성물 | |
| US20250361280A1 (en) | Conjugated hepcidin mimetics | |
| HK40094751A (en) | Polyvalent sting activating compositions and uses thereof | |
| CN115461357A (zh) | 用于递送药物活性剂的组合物和方法 | |
| US20120165268A1 (en) | P53 fusion proteins and methods of making and using thereof | |
| HK40092555A (en) | Therapeutic ph responsive compositions | |
| HK40077764B (en) | Ph responsive block copolymer compositions, micelles, and methods of use | |
| JP2025532958A (ja) | EphA2結合保留ペプチド及びそれを含む組成物 | |
| HK40096444A (en) | Antibody-tlr agonist conjugates, methods and uses thereof | |
| HK40062074A (en) | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230816 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240903 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240903 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251002 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260402 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260701 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260706 |